Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Diabetic Kidney Disease (DKD) is a progressive kidney disorder affecting patients with type 2 diabetes, characterized by albuminuria, reduced glomerular filtration, and heightened cardiovascular risk. Globally, approximately 40-50% of individuals with type 2 diabetes develop DKD, highlighting its significant burden. The diabetic kidney disease pipeline analysis by Expert Market Research emphasizes robust clinical activity across small molecules, monoclonal antibodies, peptides, and gene therapies, reflecting strong innovation aimed at slowing progression, improving renal function, and reducing disease-related complications worldwide.
-
Major companies involved in the diabetic kidney disease pipeline analysis include Renal Corp., Alebund Pharmaceuticals, and others.
-
Leading drugs currently in the pipeline include R3R01, AP303 150μg, and others.
-
Rapid innovation across molecule classes is uniquely driving the DKD pipeline. Small molecules like SGLT2 inhibitors and ABCA1 inducers target metabolic and lipid pathways, while monoclonal antibodies address inflammation and fibrosis. Peptide therapeutics improve vascular and metabolic regulation, whereas emerging gene therapies correct upstream genetic drivers, collectively reshaping DKD drug development.
Report Coverage
The Diabetic Kidney Disease Pipeline Analysis Report by Expert Market Research gives comprehensive insights into diabetic kidney disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for diabetic kidney disease. The diabetic kidney disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The diabetic kidney disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with diabetic kidney disease treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to diabetic kidney disease.
Read more about this report - Request a Free Sample
Diabetic Kidney Disease Pipeline Outlook
Diabetic kidney disease (DKD) is a common complication of type 2 diabetes, characterized by progressive kidney damage, albuminuria, and declining glomerular filtration. Treatment strategies focus on slowing disease progression, controlling blood glucose and blood pressure, and reducing cardiovascular risk.
Diabetic kidney disease treatment strategies focus on slowing disease progression through optimized glycemic and blood pressure control, along with therapies aimed at reducing cardiovascular risk. In January 2025, the U.S. FDA approved Ozempic for patients with type 2 diabetes and chronic kidney disease, representing a significant advancement. This therapy not only improves glycemic control but also helps reduce DKD-related complications, including cardiovascular events, dialysis requirement, and the need for kidney transplantation, expanding patient management options.
Diabetic Kidney Disease Epidemiology
Diabetic kidney disease (DKD) develops in roughly 40–50% of individuals with type 2 diabetes mellitus (T2DM) worldwide, reflecting the disease’s heavy burden in diabetic populations. DKD arises through persistent hyperglycemia, hypertension, oxidative stress, and inflammatory/fibrotic pathways that damage glomerular structures, reduce eGFR, and cause albuminuria. Risk escalates over time, especially in patients with longer duration of diabetes, older age, and comorbid metabolic conditions, driving chronic kidney disease and eventual renal decline.
Diabetic Kidney Disease – Pipeline Therapeutic Assessment
This section of the report covers the analysis of diabetic kidney disease drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
The diabetic kidney disease pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Peptides
- Gene Therapies
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Diabetic Kidney Disease Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total diabetic kidney disease clinical trials. Phase I represents 13%, phase III 16%, phase IV 25%, highlighting the distribution of clinical development across different stages and emphasizing the strong focus on mid-stage trials to evaluate safety and preliminary efficacy before progressing to pivotal studies.
Diabetic Kidney Disease Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the diabetic kidney disease pipeline analysis include small molecules, monoclonal antibodies, peptides, and gene therapies. The diabetic kidney disease report provides a comparative assessment of these classes across all clinical-stage assets. In November 2025, Bayer reported pivotal Phase III FINE-ONE results showing KERENDIA® (finerenone) reduced UACR by 25% in T1D-CKD patients on standard care, reinforcing the growing impact of next-generation renal therapeutics in the DKD pipeline.
Diabetic Kidney Disease Clinical Trials – Key Players
The EMR report for the diabetic kidney disease pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed diabetic kidney disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in diabetic kidney disease clinical trials:
- Renal Corp.
- Alebund Pharmaceuticals
- Daewoong Pharmaceutical Co. Ltd
- Biocity Biopharmaceutics Co., Ltd
- Walden Biosciences
- Tasly Pharmaceutical Group Co., Ltd
- Aptabio Therapeutics, Inc.
- Palatin Technologies
Diabetic Kidney Disease – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for diabetic kidney disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of diabetic kidney disease drug candidates.
Drug: R3R01
R3R01 is an investigational small molecule ABCA1 inducer being developed to reduce intracellular lipid accumulation in renal cells, thereby lowering proteinuria and preserving kidney function in genetic and non-genetic glomerular diseases. Clinical programs target Alport syndrome and steroid-resistant FSGS, with phase II and early phase studies assessing safety and proteinuria reduction. The agent is being advanced by River3/Renal-aligned developers in collaboration with nephrology trial networks, with multiple registrational-style studies ongoing to evaluate renal outcome signals.
Drug: AP303 150μg
AP303 150 µg is a small-molecule renal agent from Alebund Pharmaceuticals that inhibits sodium-dependent phosphate transporters and has shown renal-protective effects in preclinical ADPKD and diabetic nephropathy models. AP303 completed a first-in-human study and received FDA orphan designation for ADPKD; development is progressing toward phase II evaluation to assess renal survival and function. Alebund positions AP303 as part of a focused renal pipeline targeting CKD, ADPKD and diabetic kidney disease.
Drug: SGLT2 inhibitor
SGLT2 inhibitors are an established class that reduces renal glucose reabsorption, lower intraglomerular pressure, and slow diabetic kidney disease progression; large trials (EMPA-KIDNEY, CREDENCE, DAPA-CKD) show consistent cardiorenal benefit and reduced ESKD risk. Multiple companies, including Boehringer-Lilly (empagliflozin), AstraZeneca (dapagliflozin), and Janssen (canagliflozin), continue trials and label expansions in CKD and T2D populations, making SGLT2 inhibitors foundational therapy for DKD management.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Diabetic Kidney Disease Pipeline Insight Report
- Which companies/institutions are leading the diabetic kidney disease drug development?
- What is the efficacy and safety profile of diabetic kidney disease pipeline drugs?
- Which company is leading the diabetic kidney disease pipeline development activities?
- What is the current diabetic kidney disease commercial assessment?
- What are the opportunities and challenges present in the diabetic kidney disease pipeline landscape?
- What is the efficacy and safety profile of diabetic kidney disease pipeline drugs?
- Which company is conducting major trials for diabetic kidney disease drugs?
- Which companies/institutions are involved in diabetic kidney disease collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in diabetic kidney disease?
Reasons To Buy This Report
The Diabetic Kidney Disease Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for diabetic kidney disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into diabetic kidney disease collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Looking for specific insights?
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share